Pharvaris (NASDAQ:PHVS - Get Free Report) traded up 5.3% during mid-day trading on Tuesday . The company traded as high as $19.84 and last traded at $19.34. 6,321 shares traded hands during trading, a decline of 86% from the average session volume of 46,693 shares. The stock had previously closed at $18.36.
Pharvaris Price Performance
The company's 50-day moving average price is $19.42 and its 200-day moving average price is $19.33. The company has a market cap of $999.78 million, a P/E ratio of -6.83 and a beta of -3.06.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of PHVS. Jane Street Group LLC bought a new position in Pharvaris during the 3rd quarter worth $526,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Pharvaris during the third quarter worth approximately $906,000. State Street Corp bought a new stake in shares of Pharvaris in the third quarter valued at approximately $1,000,000. Geode Capital Management LLC raised its holdings in Pharvaris by 18.4% in the 3rd quarter. Geode Capital Management LLC now owns 36,977 shares of the company's stock valued at $685,000 after acquiring an additional 5,753 shares in the last quarter. Finally, Novo Holdings A S lifted its position in shares of Pharvaris by 47.7% during the 2nd quarter. Novo Holdings A S now owns 1,725,000 shares of the company's stock valued at $32,430,000 after acquiring an additional 556,970 shares during the period.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Read More
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
